Yuki Tanaka

Fukuoka, 8111395, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab.

Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab.

Journal: Cancers
Published: November 01, 2025

Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects.

Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects.

Journal: Current oncology (Toronto, Ont.)
Published: May 31, 2025

Zinc Deficiency as a General Feature of Cancer: a Review of the Literature.

Zinc Deficiency as a General Feature of Cancer: a Review of the Literature.

Journal: Biological trace element research
Published: May 18, 2023

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)
Published: November 03, 2022

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.

Journal: Medicine
Published: October 12, 2022

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: August 20, 2022

Undifferentiated embryonal sarcoma of the liver occurring in an adolescent: a case report with genomic analysis.

Undifferentiated embryonal sarcoma of the liver occurring in an adolescent: a case report with genomic analysis.

Journal: Surgical case reports
Published: August 05, 2022

Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.

Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.

Journal: Clinical journal of gastroenterology
Published: January 27, 2021

Risk factors for de novo hepatitis B during solid cancer treatment.

Risk factors for de novo hepatitis B during solid cancer treatment.

Journal: World journal of clinical cases
Published: August 31, 2020

Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.

Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.

Journal: Virchows Archiv : an international journal of pathology
Published: August 06, 2019

Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.

Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.

Journal: Human pathology
Published: April 22, 2016

Reply to Letter to the Editor by Pujals et al.

Reply to Letter to the Editor by Pujals et al.

Journal: Pathology international
Published: May 06, 2015
Showing 1-12 of 21

Last Updated: 09/26/2026